Claims for Patent: 12,213,982

Summary for Patent: 12,213,982

Title:	Pharmaceutical compositions comprising sepiapterin and uses thereof
Abstract:	The present invention features pharmaceutical compositions including sepiapterin, or a pharmaceutically acceptable salt and/or co-crystal thereof, and methods for the treatment of tetrahydrobiopterin-related disorders (e.g., tetrahydrobiopterin deficiency or phenylketonuria) with such compositions.
Inventor(s):	Daniel E. Levy
Assignee:	PTC Therapeutics Inc , PTC Therapeutics MP Inc
Application Number:	US18/235,486
Patent Claims:	1. A method of treating a tetrahydrobiopterin-related disorder selected from tetrahydrobiopterin deficiency and phenylketonuria in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an effective amount of sepiapterin and a pharmaceutically acceptable carrier, wherein the relative amount of antioxidant to sepiapterin is between 0 and 20% wt/wt; wherein the antioxidant, when present, is ascorbic acid, an ester of ascorbic acid, or a salt of ascorbic acid; and wherein from about 2.5 mg sepiapterin per kilogram of body weight of the subject (mg/kg) to about 150 mg/kg is administered. 2. The method of claim 1, wherein from about 40 mg/kg to about 150 mg/kg is administered. 3. The method of claim 1, wherein from about 60 mg/kg to about 120 mg/kg is administered. 4. The method of claim 1, wherein from about 40 mg/kg to about 60 mg/kg is administered. 5. The method of claim 1, wherein from about 2.5 mg/kg to about 20 mg/kg is administered. 6. The method of claim 1, wherein the tetrahydrobiopterin-related disorder is phenylketonuria. 7. The method of claim 1, wherein the tetrahydrobiopterin-related disorder is a tetrahydrobiopterin deficiency. 8. The method of claim 7, wherein the tetrahydrobiopterin deficiency is primary tetrahydrobiopterin deficiency. 9. The method of claim 1, wherein the pharmaceutical composition comprises less than 1.3% of lactoylpterin by weight of the combined amount of sepiapterin and lactoylpterin in the composition. 10. The method of claim 1, wherein the pharmaceutical composition is stable at room temperature for at least 6 months. 11. The method of claim 1, wherein the pharmaceutical composition is formulated as a powder. 12. The method of claim 1, wherein the composition further comprises a dispersant selected from crosslinked polyvinylpyrrolidone, carboxymethylcellulose, croscarmellose sodium, starch, or alginic acid, wherein the pharmaceutical composition comprises 0.5-1.5% dispersant by total weight. 13. The method of claim 12, wherein the dispersant is croscarmellose sodium, wherein the composition comprises 1% croscarmellose sodium by weight. 14. The method of claim 1, wherein the composition further comprises an anti-caking agent or bulking agent selected from colloidal silicon dioxide, microcrystalline cellulose, tricalcium phosphate, microcrystalline cellulose, magnesium stearate, sodium bicarbonate, sodium ferrocyanide, potassium ferrocyanide, calcium ferrocyanide, calcium phosphate, sodium silicate, colloidal silicon dioxide, calcium silicate, magnesium trisilicate, talcum powder, sodium aluminosilicate, potassium aluminum silicate, calcium aluminosilicate, bentonite, aluminum silicate, stearic acid, and polydimethylsiloxane, wherein the composition comprises about 60-80% anti-caking or bulking agent by total weight. 15. The method of claim 14, wherein the anti-caking or bulking agents are microcrystalline cellulose and silicon dioxide, wherein the composition comprises about 63% microcrystalline cellulose by weight and about 6% colloidal silicon dioxide by weight. 16. The method of claim 1, wherein the antioxidant is selected from ascorbic acid, ascorbyl palmitate, ascorbyl myristate, ascorbyl stearate, or sodium ascorbate. 17. The method of claim 16, wherein the antioxidant is ascorbic acid. 18. The method of claim 1, wherein the composition is substantially free of antioxidant. 19. The method of claim 1, wherein the pharmaceutical composition comprises about 25% sepiapterin by total weight.